Jan Kaiserle

For the millions of individuals navigating life after a cancer diagnosis, the path toward long-term health is often paved with difficult questions about lifestyle choices, especially diet. A groundbreaking study now provides a compelling piece of that puzzle, revealing a significant and concerning

With deep expertise in biopharma innovation and oncology research and development, Ivan Kairatov offers a unique perspective on the latest breakthroughs in cancer treatment. Today, we delve into the recent positive opinion from European regulators for AstraZeneca’s Imfinzi in combination with

For individuals grappling with the relentless and often disfiguring effects of cutaneous lupus erythematosus, the path to effective treatment has been long and fraught with limited options, but a significant development from Biogen offers a new beacon of hope. The U.S. Food and Drug Administration

For decades, the field of oncology has striven for precision, tailoring therapies to the unique genetic fingerprint of a tumor, yet a fundamental biological variable present in every cell of a patient's body has been largely overlooked: their sex. A groundbreaking study now challenges this

With us today is Ivan Kairatov, a biopharma expert with deep knowledge of technological innovation in research and development. We're diving into the groundbreaking results of a recent large-scale trial that's set to redefine breast cancer screening, exploring how artificial intelligence is not

The significant disparity in survival rates between early and late-stage breast cancer diagnoses has long propelled the search for more effective and frequent screening technologies beyond the established annual mammogram. The development of portable breast ultrasound represents a significant

In the high-stakes world of pharmaceutical development, not all clinical successes translate to commercial triumphs, a reality starkly illustrated when Amgen announced it was terminating its partnership with Kyowa Kirin for the eczema drug rocatinlimab, handing back the rights to a once-promising

A strategic maneuver from the titan of mRNA vaccine technology has shifted a potentially life-changing therapy for a rare disease into the hands of a specialized pharmaceutical firm, signaling a significant recalibration of priorities for both companies. In a deal that highlights the complex

A remarkable scientific breakthrough now suggests that the earliest biological indicators for type 1 diabetes can be detected at the moment of a child's birth, long before any clinical symptoms appear. Research emerging from a collaborative effort between scientists at the University of Florida and

We're joined today by Ivan Kairatov, a biopharma expert whose work at the intersection of technology and R&D provides a unique lens on the future of oncology. While immune checkpoint inhibitors have revolutionized cancer treatment, the stark reality is that most patients don't respond, largely due